Projects per year
Personal profile
Biography
Dr. Donia Moujalled completed her PhD in 2012 at The Walter and Eliza Hall Institute of Medical Research in the Cell Death and Cell Signaling division, led by Prof. David Vaux. During her PhD, Dr. Moujalled examined the role of receptor interacting protein kinases in cell death induced by tumour necrosis factor receptor 1. She continued to work as a post-doctoral researcher in Prof. Vaux's lab 2012- 2013, recieving funding from The Cancer Austalia Foundation, to characterise RIPK3 and MLKL in necroptosis signaling induced by TNF.
In 2014, she moved to the Austrlian Centre for Blood Diseases, Monash University based at The Alfred Hospital. She joined the Leukemia Research Group, led by A/Prof. Andrew Wei. Her research focus is on developing in vivo pre-clinical models to examine BH3 mimetic compounds targeting pro-survival proteins BCL-2 and MCL1 in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
External positions
Honorary, Alfred Hospital
2014 → …
Research area keywords
- Acute myeloid leukaemia
- Acute lymphoblastic leukaemia
- apoptosis
- BH3 mimetics
- BCL-2
- MCL1
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
Thijssen, R., Diepstraten, S. T., Moujalled, D., Chew, E., Flensburg, C., Shi, M. X., Dengler, M. A., Litalien, V., MacRaild, S., Chen, M., Anstee, N. S., Reljić, B., Gabriel, S. S., Djajawi, T. M., Riffkin, C. D., Aubrey, B. J., Chang, C., Tai, L., Xu, Z., Morley, T. & 16 others, , 20 May 2021, In: Blood. 137, 20, p. 2721-2735 15 p.Research output: Contribution to journal › Article › Research › peer-review
15 Citations (Scopus) -
Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models
Morrish, E., Copeland, A., Moujalled, D. M., Powell, J. A., Silke, N., Lin, A., Jarman, K. E., Sandow, J. J., Ebert, G., Mackiewicz, L., Beach, J. A., Christie, E. L., Lewis, A. C., Pomilio, G., Fischer, K. C., MacPherson, L., Bowtell, D. D. L., Webb, A. I., Pellegrini, M., Dawson, M. A. & 4 others, , 27 Oct 2020, In: Blood Advances. 4, 20, p. 5062-5077 16 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access3 Citations (Scopus) -
Cotargeting BCL-2 and MCL-1 in high-risk B-ALL
Moujalled, D. M., Hanna, D. T., Hediyeh-Zadeh, S., Pomilio, G., Brown, L., Litalien, V., Bartolo, R., Fleming, S., Chanrion, M., Banquet, S., Maragno, A. L., Kraus-Berthier, L., Schoumacher, M., Mullighan, C. G., Georgiou, A., White, C. A., Lessene, G., Huang, D. C. S., Roberts, A. W., Geneste, O. & 6 others, , 23 Jun 2020, In: Blood Advances. 4, 12, p. 2762-2767 6 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access14 Citations (Scopus) -
Combining BH3-Mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
Moujalled, D. M., Pomilio, G., Ghiurau, C., Ivey, A., Salmon, J., Rijal, S., Macraild, S., Zhang, L., Teh, T. C., Tiong, I. S., Lan, P., Chanrion, M., Claperon, A., Rocchetti, F., Zichi, A., Kraus-Berthier, L., Wang, Y., Halilovic, E., Morris, E., Colland, F. & 7 others, , 1 Apr 2019, In: Leukemia. 33, a, p. 905-917 13 p.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile83 Citations (Scopus) -
AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies
Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., Cardozo, M., Houze, J., Li, Y., Lucas, B., Paras, N. A., Wang, X., Taygerly, J. P., Vimolratana, M., Zancanella, M., Zhu, L. & 18 others, , 1 Dec 2018, In: Cancer Discovery. 8, 12, p. 1582-1597 16 p.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile194 Citations (Scopus)
Prizes
-
ACBD best post-doctoral research fellow presentation
Moujalled, Donia (Recipient), 2019
Prize: Prize (including medals and awards)
-
EMCR Best publication-Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
Moujalled, Donia (Recipient), 2019
Prize: Prize (including medals and awards)
-
New Directions in Leukemia Research Post-doctoral Research Fellow Travel award
Moujalled, Donia (Recipient), 2020
Prize: Prize (including medals and awards)